E. David Crawford, MD, Author at Grand Rounds in Urology

E. David Crawford, MD

University of California, San Diego

La Jolla, California

Researcher-physician E. David Crawford, MD, has devoted his medical career to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States. He is currently a Professor of Urology and Jack A. Vickers Director of Prostate Research at the University of California, San Diego. Dr. Crawford earned his MD from the University of Cincinnati and his postgraduate training, which included an internship and residency in Urology, at the Good Samaritan Hospital in Cincinnati, Ohio. He subsequently completed a fellowship in Genitourinary Cancer at the University of California, Los Angeles. Dr. Crawford is an internationally-recognized expert in benign prostate hypertrophy, urologic cancers, and, in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies.

Dr. Crawford has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and has provided more than 2,200 educational talks for patients and physicians. In an effort to raise public awareness about prostate health, Dr. Crawford in 1989 founded the Prostate Conditions Education Council (PCEC) and currently serves as its chair. The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates, and its advocacy for free or low-cost prostate screening has affected the lives of millions of American men. Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Dr. Crawford has served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. Dr. Crawford's involvement in the national prostate cancer arena has been widely recognized, and he has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999. In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf. Crawford again won a prestigious 'Freddie Award" in 2005. He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal. He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018, he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine, and in May of 2019, he received the Presidential citation from the American Urological Association, recognizing his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D., annual award for excellence in medicine by the Florida State Medical Association.

LDR Brachytherapy in Community Practice: Expanding Access Through Collaborative Care

E. David Crawford, MD, Garrett D. Pohlman, MD, Daniel Decker, MD and Steven M. Kurtzman, MD | Oct 2026

E. David Crawford, MD, Garrett D. Pohlman, MD, Daniel Decker, MD, and Steven Kurtzman, MD, discuss integrating LDR brachytherapy into community and rural practices through collaboration between urology and radiation oncology.

PET Tumor Board: Discordant PSMA and FDG PET Findings in Concurrent Adenocarcinoma and Neuroendocrine Prostate Cancer

E. David Crawford, MD, Daniel P. Petrylak, MD, Sherief H. Gamie, MD, PhD, Wayne G. Brisbane, MD and Peter J. Rossi, MD, FABS, FASTRO | Oct 2026

Experts review a rare case involving the coexistence of metastatic neuroendocrine prostate cancer and recurrent adenocarcinoma with discordant FDG and PSMA PET imaging findings.

PET Tumor Board: Negative PSMA PET Imaging in Biochemical Recurrence with Incidental Detection of Primary Lung Adenocarcinoma

E. David Crawford, MD, Daniel P. Petrylak, MD, Sherief H. Gamie, MD, PhD, Wayne G. Brisbane, MD and Peter J. Rossi, MD, FABS, FASTRO | Oct 2026

Experts discuss rising PSA despite negative PSMA PET imaging and review how surveillance imaging ultimately identified an early-stage primary lung adenocarcinoma.

TARA-002 Shows Early Promise for High-Risk NMIBC in the ADVANCED-2 Phase 2 Trial

E. David Crawford, MD, Timothy N. Clinton, MD and Mark D. Tyson II, MD, MPH | Jul 2026

Dr. E. David Crawford, Dr. Timothy N. Clinton, and Dr. Mark D. Tyson II review the ADVANCED-2 Phase 2 trial, discussing the mechanism of action of TARA-002, trial design, preliminary efficacy and safety findings, repeat induction, and future clinical development for patients with high-risk non-muscle-invasive bladder cancer.

The ARACOG Study: Neurourologic Cognition

E. David Crawford, MD and Alicia K. Morgans, MD, MPH | Jul 2026

Dr. Alicia Morgans discusses ARACOG, cognitive testing, and treatment selection for patients receiving darolutamide or enzalutamide for advanced prostate cancer.